Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer

Bibliographic Details
Main Authors:	Chia-Hao Liu, Yi Chang
Format:	Article
Language:	English
Published:	Elsevier 2017-10-01
Series:	Taiwanese Journal of Obstetrics & Gynecology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455917302152

Similar Items

Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function
by: Jiajia Li, et al.
Published: (2023-01-01)

The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas
by: Nazanin Majd, et al.
Published: (2020-11-01)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
by: Stephen A. Jannetti, et al.
Published: (2020-03-01)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
by: Andrisha-Jade Inderjeeth, et al.
Published: (2022-11-01)

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
by: Maurie Markman
Published: (2018-01-01)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
by: Joseph A. De Soto, Xianyan Wang, Yohei Tominaga, Rui-Hong Wang, Liu Cao, Wenhui Qiao, Cuiling Li, Xiaoling Xu, Amanda P. Skoumbourdis, Sheila A. Prindiville, Craig J. Thomas, Chu-Xia Deng
Published: (2006-01-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
by: Stergios Boussios, et al.
Published: (2019-08-01)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
by: Ruihong Dong, et al.
Published: (2023-06-01)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
by: Daniel Harrision, et al.
Published: (2020-08-01)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
by: Emad Matanes, et al.
Published: (2021-10-01)

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer
by: A. Desnoyers, et al.
Published: (2022-03-01)

Targeted therapy with Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of solid tumours
by: Faustyna Piędel, et al.
Published: (2020-03-01)

Methods for Purification of Proteins Associated with Cellular Poly(ADP-Ribose) and PARP-Specific Poly(ADP-Ribose)
by: Rood, Jennifer E., et al.
Published: (2014)

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
by: Sarkar Oli, et al.
Published: (2009-12-01)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
by: Qin Xu, et al.
Published: (2021-11-01)

The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
by: Yingzhu Yang, et al.
Published: (2020-07-01)

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
by: M. Javle, et al.
Published: (2011-11-01)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
by: Zhimin Zhang, et al.
Published: (2020-01-01)

Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
by: Saman Sargazi, et al.
Published: (2021-09-01)

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
by: Aniello Cerrato, et al.
Published: (2016-11-01)

Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials
by: Liu Y, et al.
Published: (2018-09-01)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
by: Jeanny B Aragon-Ching
Published: (2016-01-01)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
by: Bijay Singh, et al.
Published: (2020-11-01)

Synthesis and study of new 4-quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
by: Gyozo Kulcsar, et al.
Published: (2003-06-01)

Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly (ADP-ribose) polymerase (PARP) inhibitors
by: Chaowen Shi, et al.
Published: (2023-09-01)

PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses.
by: Junqi Song, et al.
Published: (2015-05-01)

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery
by: Fernet Marie, et al.
Published: (2003-07-01)

Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer
by: Ryosuke Uekusa, et al.
Published: (2024-04-01)

Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review
by: Emilia Nowicka, et al.
Published: (2022-12-01)

Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer’s Disease
by: Felipe Salech, et al.
Published: (2020-08-01)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
by: Mathilde Malgras, et al.
Published: (2021-03-01)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
by: Jingsong Zhang
Published: (2014-06-01)

Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer.
by: Yufeng Wang, et al.
Published: (2014-01-01)

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (Russian Translation of Cochrane Plain Language Summary)
by: Karina G. Uvarova
Published: (2022-04-01)

Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer
by: V. N. Zhurman, et al.
Published: (2023-02-01)

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants.
by: Katherine E Zarn, et al.
Published: (2022-01-01)

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants
by: Katherine E. Zarn, et al.
Published: (2022-01-01)

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics
by: Iain A. Richard, et al.
Published: (2022-01-01)

Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.
by: Marine Gilabert, et al.
Published: (2014-01-01)